Pre-Exposure Prophylaxis or PrEP

Pre-exposure prophylaxis (PrEP) involves putting HIV negative people on antiretroviral drugs (ARV) with the aim of protecting them from HIV infection. This blog looks at some of the pros and cons of PrEP.

Saturday, June 23, 2012

Truvada Manufacturer Gilead Stops Funding to Critics


The Aids Healthcare Foundation (AHF) provides healthcare for HIV positive people and advocacy in the broader field of HIV health. In that capacity, the AHF has criticized the pharmaceutical company Gilead Sciences on a number of issues, including drug pricing policies.

But in addition, AHF has questioned the use of Gilead's Truvada as a pre-exposure prophylaxis (PrEP), a pill to be taken by HIV negative people to give them some protection from HIV infection. It could be taken, for example, by someone whose sexual partner is HIV positive. However, PrEP is not as effective as using a condom and it doesn't protect against other sexually transmitted infections.

More importantly, using a drug like Truvada can give rise to the development of drug resistant strains of HIV, especially in users who are unknowingly infected when they start taking the drug or who unknowingly become infected while taking it. AHF have argued that every time someone gets a prescription for Truvada, they should also be able to show that they have been tested for HIV and the result is negative.

Drug manufacturers are not known for their tolerance of public accountability; as a result of AHFs actions, Gilead have stopped their funding to AHF. This is particularly unfortunate right now because approval for Truvada as PrEP, which was expected to be rushed through the usual regulatory procedures, has now been delayed so that the requirement for a negative HIV test be stipulated. But it's likely that Gilead will continue to lobby for the right to aggressively pursue their own ends at the expense of public health.

The increasing dependence on drugs with outrageously high prices is worrying even in a wealthy country like the US. But as the country has the highest HIV prevalence in the Western world, it would be an even bigger threat to the country's public health systems if widespread resistance to Truvada were to develop. As well as resistance developing in an individual taking the drug, resistant strains of HIV can also be transmitted to others.

Also of concern is that, up until now, HIV drugs have been used by HIV positive people. The use of the same drugs by people who are HIV negative should be raising questions in people's minds about how far public health should go with what is effectively medical treatment for perfectly healthy people.

They may even ask how far it is possible for public health to go; the number of healthy people should, hopefully, far outnumber the number of sick people; it's undoubtedly a great market. But some level of drug resistance is inevitable. So are companies like Gilead stealthily creating new markets for even more costly second line drugs by vastly increasing the number of healthy people taking Truvada?

allvoices

5 comments:

NewPrevTech said...

You must work for AHF. If not, you certainly didn't bother to do any reporting, or fact finding, for this piece.

Despite their, and your, fact-free theories, a large number of ASOs in the United States support the careful, considered use of PrEP http://www.prepwatch.org/

And in Southern Africa, guidelines for the use of PrEP have just been released. http://www.sahivsoc.org/upload/documents/Southern%20African%20guidelines%20for%20the%20safe%20use%20of%20pre-exposure%20prophylaxis%20in%20men%20who%20have%20sex%20with%20men%20who%20are%20at%20risk%20for%20HIV%20infection.pdf

Everyone's not "in the tank." In fact, is was the AIDS community, and researchers, that have always led the way on new prevention technologies. This was never Gilead's idea - the idea came from advocates and reseachers.

Anyway, you don't seem to be interested in anything more complicated than AHF's histrionic agenda.

Jason Hall said...
This comment has been removed by a blog administrator.
Simon said...

Thanks for your message. What you call PrepWatch is part of AVAC, a pharmaceutical industry front group. I don't work for the AHF, but as I am not funded by any interested party, I am free to think, research and write as I see fit. I'm happy to hear that Gilead never had any interest in making money out of HIV, I'm sure their shareholders will be very relieved to know that.

Jual Obat Bius said...

nice article...

Obat Bius | Obat Bius Wanita | Jual Obat Bius


thank you for the information regards success only father / mother

Annabelle taylor said...

More than 400 million people living with Herpes in the world. Most of them suffer from the sickness and loneliness. A safe and private social channel, such as === http://www.std-meet.com, is essential for people living with STDs to meet friends, find someone in the same situation to talk and seek soul mate

Post a Comment